secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001140361-24-007259
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant posts $5.1B net income on $7.1B Telavant sale to Roche; cash at $6.7B
-----------------------------------------------------------------------------

- Net income $5.1B ($6.37 basic EPS) vs loss of $384.9M a year ago, driven by $5.3B gain on Telavant sale.
- Net cash proceeds from Telavant sale ~$5.2B; consolidated cash, cash equivalents and restricted cash $6.7B at Dec 31, 2023.
- VTAMA net product revenue $20.7M for Q3; over 300k prescriptions written by ~14k prescribers since launch.
- Batoclimab Phase 2 Graves' disease trial shows >50% response rate in initial cohort; additional data ongoing.
- Non-GAAP net loss $174.9M; R&D expenses $123.7M; SG&A $197.3M; RVT-2001 development discontinued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/0001140361-24-007259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/ef20021494_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-007259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer